Tumor Hypervascularity and hand-foot-skin reaction predict better outcomes in combination treatment of TACE and Sorafenib for intermediate hepatocellular carcinoma

Table 2 Prognostic factors for time to radiologic progression in HCC patients treated with combination treatment

Characteristics	NO. (N1 = 131)	mTTP (month)	Uni-variate HR (95%CI)	p value	Multi-variate HR1^a (95%CI)	p value	Multi-variate HR2^b (95%CI)	p value
Gender (male/female)	112/19	7.3/7.2	0.923 (0.549–1.552)	0.763
Age (< 60/≥60 years)	88/43	7.3/7.7	1.173 (0.774–1.776)	0.451
Etiology (HBV/other than HBV)	108/23	7.3/7.2	1.065 (0.653–1.736)	0.802
PLT (< 150/≥150 × 10E9/L)	74/57	7.8/5.6	0.925 (0.630–1.358)	0.691
Albumin (< 35/≥35 g/L)	20/111	12.5/6.7	0.850 (0.483–1.494)	0.571
Bilirubin (≥17/< 17 μmol/L)	50/81	6.9/8.3	1.159 (0.782–1.720)	0.462
AST (≥40/< 40 U/L)	68/63	5.6/7.8	1.246 (0.851–1.823)	0.258
ALT (≥40/< 40 U/L)	55/76	5.8/7.4	1.044 (0.708–1.540)	0.827
AFP (≥200/< 200 ng/ml)	66/65	4.9/9.3	1.174 (0.800–1.723)	0.412
Ascites (with/without)	15/116	5.7/7.3	1.291 (0.688–2.424)	0.426
Child-Pugh score (5/6/≥7)	103/20/8	7.0/6/7/21.7	0.919 (0.641–1.316)	0.644
Tumor size (≥7/< 7 cm)	70/61	5.4/10.8	1.646 (1.119–2.422)	0.011	1.900 (1.282–2.815)	0.001	1.834(1.239–2.741)	0.002
No. of HCC nodules (≥2/1)	62/69	5.4/9.6	1.338 (0.911–1.966)	0.137
Sorafenib usage (after/before TACE)	43/88	7.9/7.2	0.998 (0.670–1.488)	0.993
Vascularity (hypovascular/hypervascular)	43/88	3.7/10.2	2.643 (1.756–3.978)	< 0.001	2.807 (1.848–4.265)	< 0.001
HFSR (non-responder/responder)	60/71	5.4/9.1	1.594 (1.084–2.343)	0.018	1.500 (1.031–2.221)	0.043
Stratification^c
Group A	52	12.2	1				1
Group BC	55	6.0	1.742 (1.127–2.693)	0.012			1.868 (1.205–2.896)	0.005
Group D	24	2.9	3.741 (2.166–6.460)	< 0.001			4.108 (2.362–7.145)	< 0.001

^aMulti-variate HR1, variables of vascularity and 2HFSR60 were included in Cox-regression but not stratification
^bMulti-variate HR2, stratification was included after excepting vascularity and 2HFSR
^cGroup A: patients with both hypervascularity and HFSR-response; Group BC: patients with either hypervascularity or HFSR-response; Group D patients with hypovascularity and HFSR-nonresponse

ISSN: 1471-2407